Home » Topics » Drugs » Immuno-oncology

Immuno-oncology
RSS

Results of MAb-B1 phase I/II trial announced

May 31, 1996

IMMU-14 demonstrates evidence of activity

May 31, 1996

Approval to initiate NOVOMAb-G2 phase I studies granted by the FDA

May 31, 1996

Encouraging results of IDEC-C2B8 trial reported

May 31, 1996

Multikine trial commenced

May 31, 1996

Single-chain immunotoxin targeted to the CD40 antigen effect as cytotoxic agent

May 31, 1996

Daiwa's MGN-3 demonstrates immunotherapeutic activity

May 31, 1996

Role of DF3 in human carcinoma and potential therapeutics

May 24, 1996

Medarex presents MDX-210 phase I/II interim results

May 24, 1996

ImClone, E. Merck continue cancer vaccine collaboration

May 24, 1996

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan 9, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Jan. 9, 2026.
ADCs’ breakout 2025 and their still-unfinished potential
BioWorld Science
Over the course of the year, and continuing into the latest scientific meetings, an extraordinary breadth of new antibody-drug conjugate (ADC) designs was...
Development and characterization of anti-CD19 in vivo CAR T therapy
BioWorld Science
Shenzhen Grit Biotechnology Co. Ltd. and Shanghai Vitalgen Biopharma Co. Ltd. recently presented their work to develop and evaluate a novel anti-CD19 in vivo CAR...
Preclinical results of anti-ADAMTS13 antibody in acquired von Willebrand syndrome
BioWorld Science
The acquired von Willebrand syndrome (AVWS) is a rare bleeding disorder with laboratory findings similar to those of inherited von Willebrand disease. Researchers...